TTC22

Across TCGA pan-cancer cohorts, TTC22 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TTC22 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TTC22 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TTC22 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where TTC22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	1.000	0.484	.038	18	view →
LUAD	OS	Median	III,IV	0.879	0.328	.007	17	view →
PDAC	DFS	Quartile	II,III,IV	0.726	0.287	.006	14	view →
LSCC	DFS	Median	All	0.843	0.258	.004	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TTC22–HNSC (OS)

Open the HNSC breakdown →